RelCoVax®, a two antigen subunit protein vaccine candidate against SARS-CoV-2 induces strong immune responses in mice

The COVID-19 pandemic has spurred an unprecedented movement to develop safe and effective vaccines against the SARS-CoV-2 virus to immunize the global population. The first set of vaccine candidates that received emergency use authorization targeted the spike (S) glycoprotein of the SARS-CoV-2 virus...

Descripción completa

Detalles Bibliográficos
Autores principales: Phatarphekar, Abhishek, Vidyadhar Reddy, G.E.C., Gokhale, Abhiram, Karanam, Gopala, Kuchroo, Pushpa, Shinde, Ketaki, Masand, Girish, Pagare, Shyam, Khadpe, Nilesh, Pai, Sangita S., Vijayan, Vijita, Ramnath, R.L., Pratap Reddy, K., Rao, Praveen, Harinarayana Rao, S., Ramana, Venkata
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9189014/
https://www.ncbi.nlm.nih.gov/pubmed/35718590
http://dx.doi.org/10.1016/j.vaccine.2022.06.026

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9189014/
https://www.ncbi.nlm.nih.gov/pubmed/35718590
http://dx.doi.org/10.1016/j.vaccine.2022.06.026

Ejemplares similares